Polycystic ovary syndrome management: a review of the possible amazing role of berberine

M. Rondanelli1,2 · Vittoria Infantino3 · A. Riva4 · G. Petrangolini4 · M. A. Faliva5 · G. Peroni5 · M. Naso5 · M. Nichetti5 · D. Spadaccini5 · C. Gasparri5 · S. Perna6

Abstract

Purpose The therapy of polycystic ovary syndrome (PCOS) is based on synthetic hormones associated with lifestyle changes, but these therapies cannot be taken continuously, especially by women who would like to become pregnant. Thus, nutraceutical compounds were investigated as possible agents for treatment of PCOS. Berberine is shown to be effective against insulin resistance and obesity, particularly against visceral adipose tissue (VAT). Because of these properties, researchers theorized that berberine could be effective in PCOS treatment.

Methods The aim of this narrative review was to assess the state of the art about the use of berberine in PCOS management.

Results This review included 5 eligible studies. Despite the number of studies considered being low, the number of women studied is high (1078) and the results are interesting. Two authors find out that berberine induced a redistribution of adipose tissue, reducing VAT in the absence of weight loss and improved insulin sensitivity, quite like metformin. One author demonstrated that berberine improved the lipid pattern. Moreover, three authors demonstrated that berberine improved insulin resistance in theca cells with an improvement of the ovulation rate per cycle, so berberine is also effective on fertility and live birth rates.

Conclusions Finally, berberine is safe to use in premenopausal women who want to get pregnant and showed few side effects in all the cited studies. In conclusion, the use of berberine for PCOS is safe and promising, even if more studies are needed to create a consensus about the dosage of berberine useful for long-term therapy.

Keywords PCOS · Berberine · VAT · Insulin resistance · Nutraceutics
**Purpose**

About 5–10% of pre-menopausal women are affected by Polycystic Ovary Syndrome (PCOS) [1–4] and its treatment could be very long, but always symptom-oriented, and also dynamic and adapted to the changing circumstances and personal needs of the individual patient. Ovarian dysfunction causes metabolic disorders and hyperandrogenism; these should be counteracted by all therapeutic approaches usually used in the management of PCOS [4].

In addition to pharmacological molecules, to improve the metabolic status of women with PCOS, it is highly recommended to suggest a modification of the lifestyle and weight reduction. The goal of all these interventions is the improving of ovulation regularity and the protection against cardiovascular diseases. The clinical treatment of PCOS is often a long-term therapy, and the most commonly used drugs are combined oral contraceptives (COCs), antiandrogenic progestins, and insulin-sensitizing drugs. Anyway, these drugs could treat the respective single sign of PCOS [5].

Because of the length of the therapy that can last for the whole fertile period of a woman and, therefore, could interfere with a hypothetical pregnancy, also botanicals have been considered against PCOS. In particular, berberine (BBR) is an alkaloid plant extract widely used in Chinese Herbal Medicine against infections, hypercholesterolemia, Diabetes type 2 and cancer [6].

Berberine is also shown to be effective against insulin resistance and obesity, particularly against visceral adipose tissue in vitro and in murine models [2, 7, 8].

Berberine is a very promising botanical compound because of the few minor side effects that could present and because its target is an AMP-activated protein kinase (AMPK) common to fatty acid oxidation, glucose generation and insulin resistance [9]. Zhang et al. explained the berberine mechanism of action and after that, scientists began to hypothesize and therefore to use berberine in clinical management of dyslipidemia, diabetes type 2 and obesity in order to counteract the cardiovascular risk derived from these metabolic disorders [9–12]. Moreover, thanks to the extreme tolerance and very minor side effects on long-term treatment, the berberine is the only botanical compound included in European guidelines for the management of dyslipidemia and it is used also in patients who do not tolerate statins [13–15].

Berberine, if associated with a healthy lifestyle, improves women’s body composition and causes androgen’s reduction as pointed out by Saleem et al. [3, 8].

PCOS is an endocrine–metabolic disorder very similar to the metabolic syndrome, indeed they have a common factor: insulin resistance. Ong et al. [6] explained that insulin resistance is the key factor that could cause obesity and anovulatory cycles and actually, that should be the target of therapeutic molecules against PCOS and also Metabolic Syndrome [2, 6].

Botanical compounds are always used in traditional Chinese medicine; among those, the berberine induces an amelioration of insulin resistance if administered at a dose of 500 mg per os twice a day for 6 months, and also improves the regularity of menstrual cycle [6].

Berberine is not only used in China, but also is being administered by English medical doctors dealing with women affected by PCOS to counteract PCOS’ symptoms and signs [16]. Rooney and Pendry in their survey among English clinicians pointed out the lack of scientific literature regarding the use of herbal medicine and consequently, the lack of uniformity in herbal prescription against PCOS [16].

Given this background, the aim of the present narrative review was to assess the state of the art about the use of berberine in the management of PCOS.

**Methods**

This narrative review was written after a PubMed and SCOPUS research performed with these keywords: “Berberine”, “PCOS” with the use of Boolean AND operator to establish the logical relation between them (Fig. 1). The research was conducted by skilled operators from July to September 2018 and following Egger’s criteria for systematic reviews [17, 18]. The research was time limited (from 2000 to 2018) and restricted for Human AND/OR Humans studies to know about the state of the art of the use of berberine in women affected by PCOS diagnosed by Rotterdam criteria.

**Results**

Only five full-text papers were taken in analysis, and all of them mentioned the possible use of berberine in non-pharmacological treatment of the endocrine disorder. The results of these five studies have been shown in Table 1.

All studies conducted compared berberine with other PCOS pharmacological therapies such as combined oral contraceptives, anti-androgen drugs, metformin and monacolins to counteract cardiac risk in PCOS [19–24]. Authors found that berberine induced a redistribution of adipose tissue, reducing visceral fat mass even in the absence of weight loss, and insulin sensitivity was improved similar to metformin [19, 22]. The nutraceutical compound also improved the lipid pattern in subjects with PCOS against monacolins [21]. Berberine in women with PCOS also improved the insulin resistance in theca cells, thanks to an increase of the expression of Glut-4 in ovaries with an
Improvement of the ovulation rate per cycle; so, berberine is also effective on fertility and live birth rates in women affected by PCOS [23, 24].

Berberine is safe to use in premenopausal women who want to become pregnant and showed few side effects in all the cited studies, in particular constipation and nausea [23, 24]. Regarding specifically side effects, 3 out of 31 subjects (BBR group) complained of a bitter taste in their mouth versus 9 out of 30 subjects (MET group) suffered by nausea, vomiting, mild diarrhea and flatulence [19]. No adverse events were observed by Cicero et al. [21] and Orio et al. [25], while An et al. reported 1/50 subject (BBR group) transient gastrointestinal side effects including diarrhea vs. 2/50 subjects (Met group) gastrointestinal side effects including diarrhea [22]. Wu et al. reported that 1 subject out of 214 subject (BBR group) had constipation and nausea, no fetal abnormalities in BBR group versus 1 fetal abnormality in letrozole group resulting in termination of pregnancy [24]. All these observed side effects were transient and mild, underlining the good safety of the use of BBR in PCOS patients.

The five studies analyzed showed some differences in the design of the study and in the results; in particular, Wei et al. An et al. and Wu et al. performed their research comparing BBR vs. ethynyl estradiol + cyproterone acetate/ metformin/ letrozole, respectively (see details in Table 1). Studies have not been conducted comparing berberine with a real placebo, perhaps because of the studied target population: women of child-bearing age, so it would be probably unethical the administration of real placebo [19, 22, 24]. Only An and colleagues used a real placebo but the placebo group also underwent to ovarian stimulation like the interventions groups to become pregnant [22].

Women enrolled by Wei et al. and An et al. received lifestyle and nutritional counseling before the treatment with berberine, metformin or placebo [19, 22]; while in the study conducted by Orio et al., no lifestyle modifications were implemented [25] in spite of the fact that a good lifestyle has been demonstrated to be crucial to the amelioration of
### Table 1: Trials conducted on the effect of berberine on PCOS-premenopausal women

| First author, year (References) | Setting | Number of subject (only F) | Inclusion criteria | Type of intervention | Control group | Intervention group 1 | Intervention group 2 | Duration | Changes in intervention group/s | Changes in control group | Conclusions | Study design (evidence level) |
|----------------------------------|---------|----------------------------|--------------------|----------------------|---------------|----------------------|----------------------|---------|-------------------------------|--------------------------|------------|-------------------------------|
| Wei (2012) [19]                  | Clinical Centre of Reproductive Medicine (Harbin, China) | 100 subjects enrolled (11 lost to follow up or left the protocol) | PCOS (Rotterdam Criteria) and insulin resistance (HOMA-IR > 3.8 or FGIR < 4.5) | All groups received nutritional instruction to limit fat and carbohydrate intake + physical exercise (30 min/day). Control group: placebo + CPA Intervention group 1: BBR hydrochloride + CPA Intervention group 2: MET + CPA | \(N=28\) (age = 26.75 ± 2.62). EE + CPA 35 mcg + 2 mg/day | \(N=31\) (age = 25.74 ± 2.66). BBR hydrochloride + CPA 500 mg + 2 mg × 3 times/day | \(N=30\) (age = 26.03 ± 2.82). MET + CPA 500 mg + 2 mg × 3 times/day | 3 months | ↓ WC, WHR, HOMA-IR, <sup>p</sup> < 0.01 | ↓ FPG, FIN, HOMA-IR, FGIR, TC, LDL, TT, FAI, HHbG, TT (<sup>p</sup> < 0.05) | ↑ HDL, SHBG non statistically significant between groups | RCT double-blind (level 1b) |
| Orio (2013) [25]                | Salerno University Hospital | 100 subjects enrolled | PCOS (Rotterdam Criteria) and obesity | No lifestyle modification during intervention. Administration of Berberol™ (PharmExtracta, Pontenure, Italy): 588 mg Berberis aristata titered as 85% and 105 mg of Silybum marianum titered < 60% 1 tablet x 2 times/day | \(N=50\) obese women (no intervention) (age = 24.12 ± 3.6) (BMI = 31.8 ± 1.4) | \(N=50\) PCOS and obese women (age = 25.0 ± 3.5) (BMI = 32.8 ± 2.4) | – | 6 months | ↓ HOMA-IR, AUC <sub>INS</sub>, TC, LDL, TRG, TT, androstenedione (<sup>p</sup> < 0.01 within group) | ↓ SHBG (<sup>p</sup> < 0.01 within group) | Control group show an IR and hormonal profile better than PCOS + obese women either first (<sup>p</sup> < 0.01) and after (<sup>p</sup> < 0.01) BBR intervention for all parameters considered | Prospective CT (level 2b) |
### Table 1 (continued)

| First author, year (References) | Setting | Number of subject (only F) | Inclusion criteria | Type of intervention | Control group | Intervention group 1 | Intervention group 2 | Duration | Changes in intervention group/s | Changes in control group | Conclusions | Study design (evidence level) |
|----------------------------------|---------|----------------------------|-------------------|---------------------|---------------|---------------------|---------------------|----------|-------------------------------|--------------------------|-------------|-----------------------------|
| Cicero (2014) [21] | Internal Medicine, Aging and Kidney disease Department, University of Bologna | 84 outpatients subjects enrolled | Age from 18 to 45 years; LDL > 130 mg/dL after oral oestroprogestins therapy against PCOS or for pure contraception | All groups: 3-month lipid-lowering diet before the intervention study, then 3-month nutraceutical intervention with BBR 500 mg/tab/day + monacolins 3 mg/tab/day | Non PCOS patients N=40 (age=29.3 ± 5.6) | PCOS patients N=44 (age=26.5 ± 6) | – | 3 months + 3 months | ↓ PCR (p = 0.024) between groups after nutraceutical intervention | – | There are not changes in HOMA-IR, nor FPG or HDL | Prospective CT (level 2b) |
| An (2014) [22] | Clinical Centre of Reproductive Medicine (Harbin, China) | 150 subjects enrolled (128 completed the study) | PCOS (Rotterdam Criteria) with previous unsuccessfully IVF treatment | Treatment with placebo: tablets similar to BBR and MET. BBR: 500 mg x 3 times/day. MET: 500 mg x 3 times/day. All groups: after 3 months undergoing ovarian stimulation | Placebo group N=43 (age=28.4 ± 4) | MET group N=41 (age=28.7 ± 4.2) | BBR group N=44 (age=28.3 ± 3.8) | 12 weeks | ↓ BMI, TC, LDL (p<0.05) BBR vs MET/placebo ↓ WC, WHR, TT, SHBG, FAI, FPG, FIN, HOMA-IR (p<0.05) BBR/MET vs placebo ↑ Live birth (p<0.05) BBR vs MET/placebo | // | Berberine is safety to use in premenopausal women and improves, more than metformin, metabolic profile and the response to ovarian stimulation and finally the percentage of live birth in PCOS women undergone to IVF | RCT double-blind (level Ib) |
Table 1 (continued)

| First author, year (References) | Setting | Number of subject (only F) | Inclusion criteria | Type of intervention | Control group | Intervention group 1 | Intervention group 2 | Duration | Changes in intervention group/s | Changes in control group | Conclusions |
|---------------------------------|---------|---------------------------|-------------------|--------------------|---------------|---------------------|---------------------|----------|-------------------------------|------------------------|-------------|
| Wu (2016) [24] China (19 hospitals) | 644 subjects enrolled | Age from 20 to 40 years; PCOS (Rotterdam Criteria); at least one open fallopian tube and normal uterine cavity; male partner with normal sperm concentration and motility; 1 year of infertility | Letrozole group (letrozole + BBR placebo) N=215 (age=27.8 ± 3.6) | BBR or BBR (letrozole + BBR placebo) N=215 (age=27.8 ± 3.6) | BBR group (letrozole + BBR placebo) N=214 (age=27.8 ± 3.7) | Combination group (letrozole + berberine) N=215 (age=27.8 ± 3.6) | 6 months | [BMI](p<0.01), WC (p<0.05) within BBR group. *Ovulation (p<0.01) BBR group vs. Letrozole group | [Live births](p<0.05) Letrozole group and Combination group vs. BBR group | Berberine improves metabolic profile in PCOS women and not affects the improvement of live birth rates achieved by letrozole |

*HOMA-IR homeostasis model assessment-insulin resistance, FGIR fasting glucose insulin ratio, EE ethinyl estradiol, CPA cyproterone acetate, BBR berberine, MET metformin, WC waist circumference, WHR waist/hip ratio, FPG fasting glucose; FIN fasting insulin, TC total cholesterol, LDL low density lipoprotein cholesterol, FAI free androgen index, HDL high density lipoprotein cholesterol, SHBG sex hormone-binding globulin, TT total testosterone, TRG triglycerides, IVF in vitro fertilization, BMI body mass index, AUC area under the curve-insulin, RCT randomized clinical trial, CT clinical trial

The study design was a multicenter, randomized, double-blind clinical trial involving 215 PCOS women aged 27.8 ± 3.6 years enrolled from 19 hospitals in China. The study aimed to evaluate the efficacy of berberine in improving metabolic parameters and live birth rates in PCOS women. The participants were randomly assigned to three groups: the letrozole group (N=215), the letrozole + berberine group (N=214), and the placebo group (N=215). The study duration was 6 months.

The primary outcome of the study was live birth rate, and the secondary outcomes included changes in metabolic parameters such as BMI, WC, and fasting glucose and insulin levels. The results showed that berberine improved the live birth rate compared to the placebo group (p<0.05). The combination of letrozole and berberine was more effective than the letrozole group alone (p<0.05).

The study concluded that berberine is a promising drug for improving live birth rates and metabolic parameters in PCOS women. Further studies are needed to confirm these findings and explore the underlying mechanisms.
of literature about the use of berberine in the treatment of PCOS, and shows the need to conduct more clinical trials on this topic to create a consensus regarding the amount of berberine useful in creating positive effects in PCOS women in a long-term therapy.

Conclusions

Despite the number of studies taken into consideration in this review being low, the number of women considered in these 5 studies is high (1078), and the results of these studies are interesting.

Two authors found out that berberine induced a redistribution of adipose tissue, reducing visceral fat mass even in the absence of weight loss, and insulin sensitivity was improved similar to metformin. One author demonstrated that berberine improved the lipid pattern. Moreover, three authors demonstrated that berberine improved the insulin resistance in theca cells with an improvement of the ovulation rate per cycle; so berberine is also effective on fertility and live birth rates. Finally, berberine may be considered as a safe botanical compound to use in premenopausal women who want to become pregnant, because of the few side effects showed in the five reported studies. Furthermore, scientific literature provides a large number of studies which reported safety and tolerability on long-term treatment with berberine in humans. In conclusion, the use of berberine in women with PCOS is very promising, even if more clinical studies are needed to confirm the safety and the efficacy of the berberine associated with other pharmacological compounds used in long-term therapy of PCOS. Besides further studies are needed to create a consensus regarding the dosage of berberine useful to create positive effects in PCOS women, even in long-term therapy.

Author contributions  MR project development, manuscript writing. VI manuscript writing, data management, data analysis. AR project development, manuscript writing. GP project development and administration. MAF data collection, review. MN data collection, review. DS data collection, review. CG data collection, review. SP data management, data analysis, review.

Funding  None.

Compliance with ethical standards

Conflict of interest  None to disclose, except that Riva A. and Petrangolini G. are Indena’s employees.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Escobar-Morreale HF (2018) Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 14:270–284. https://doi.org/10.1038/nrendo.2018.24
2. Wang Y, Fu X, Xu J et al (2016) Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome. Sci Rep. https://doi.org/10.1038/srep28089
3. Rondanelli M, Perna S, Faliva M et al (2014) Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena. Arch Gynecol Obstet 290:1079–1092. https://doi.org/10.1007/s00404-014-3433-z
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
5. Rocca ML, Venturella R, Moccia R et al (2015) Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opin Pharmacother 16:1369–1393. https://doi.org/10.1517/14656566.2015.1047344
6. Ong M, Peng J, Jin X, Qu X (2017) Chinese herbal medicine for the optimal management of polycystic ovary syndrome. Am J Chin Med 45:405–422. https://doi.org/10.1124/ajcm.2016.115737
7. Liu D, Zhang Y, Liu Y et al (2018) Berberine modulates gut microbiota and reduces insulin resistance via the TLR4 signaling pathway. Exp Clin Endocrinol Diabetes. https://doi.org/10.1055/s-0043-125066
8. Saleem F, Rizvi SW (2017) New therapeutic approaches in obesity and metabolic syndrome associated with polycystic ovary syndrome. Cureus 9:e1844. https://doi.org/10.7759/cureus.1844
9. Zhang BB, Zhou G, Li C (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9:407–416. https://doi.org/10.1016/j.cmet.2009.03.012
10. Catapano AL, Graham I, De Backer G et al (30581) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–30581. https://doi.org/10.1093/eurheartj/ehw272
11. Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57:712–717. https://doi.org/10.1016/j.metabol.2008.01.013
12. Zhang Y, Li X, Zou D et al (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93:2559–2565. https://doi.org/10.1210/jc.2007-2404
13. Poli A, Barbagallo CM, Cicero AFG et al (2018) Nutraceuticals and functional foods for the control of plasma cholesterol levels An intersociety position paper. Pharmacol Res 134:51–60. https://doi.org/10.1016/j.phrs.2018.05.015
14. Di PIERRO F, Bellone I, Rapacioli G, Putignano P (2015) Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic
patients intolerant to statins. Diabetes Metab Syndr Obes Targets Ther 8:89–96. https://doi.org/10.2147/DMSO.S78877

15. Di Pierro FF, Villanova N, Agostini F et al (2012) Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes Targets Ther 5:213. https://doi.org/10.2147/DMSO.S33718

16. Rooney S, Pendry B (2014) Phytotherapy for polycystic ovarian syndrome: a review of the literature and evaluation of practitioners’ experiences. J Herb Med 4:159–171. https://doi.org/10.1016/j.jhermed.2014.05.001

17. Egger M, Smith GD, Altman DG (2001) Systematic reviews in health care: meta-analysis in context. BMJ Books, London

18. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097

19. Wei W, Zhao H, Wang A et al (2012) A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol 166:99–105. https://doi.org/10.1530/EJE-11-0616

20. Li Y, Ma H, Zhang Y et al (2013) Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial. Trials 14:226. https://doi.org/10.1186/1745-6215-14-226

21. Cicero AFG, Reggi A, Parini A et al (2014) Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia. High Blood Press Cardiovasc Prev 21:221–226. https://doi.org/10.1007/s40292-014-0052-5

22. An Y, Sun Z, Zhang Y et al (2014) The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf) 80:425–431. https://doi.org/10.1111/cen.12294

23. Li Y, Kuang H, Shen W et al (2013) Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial. BMJ Open 3:e003934. https://doi.org/10.1136/bmjopen-2013-003934

24. Wu X-K, Wang Y-Y, Liu J-P et al (2016) Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome. Fertil Steril 106:757–765.e1. https://doi.org/10.1016/j.fertnstert.2016.05.022

25. Orio F, Muscogiuri G, Palomba S et al (2013) Berberine improves reproductive features in obese Caucasian women with polycystic ovary syndrome independently of changes of insulin sensitivity. ESPEN J. https://doi.org/10.1016/j.clnme.2013.07.002

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.